Seattle Genetics (SGEN), Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. today announced completion of enrollment for the enfortumab vedotin EV-201 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
